Reprogramming Cancer And Competing With China With Earli's Cyriac Roeding

Episode 326

0:00-59:51

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Cyriac Roeding talks about cofounding and leading Earli, a "bioAI" company using synthetic DNA switches and cancer-binding lipid nanoparticles to transform cancer cells into immune therapy-producing factories in vivo. Cyriac also discusses China’s newest five-year plan for biotech (2026 to 2030), why U.S. funding cycles are pushing innovation offshore, and how a U.S. sovereign wealth fund could support preclinical and early-stage drug development leadership at home. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Publisher

Business Of Biotech

Published

October 5, 2026

Duration

1h

Format

Podcast

Category

Issues · Business

Source

RSS feed

Host

Ben Comer

BO

Business Of Biotech

@businessofbiotech

#reprogrammingcancer #competing #earliscyriacroeding #management #lifesciences

The Nile